Brain Function Changes Following COVID-19 Infection
Cortical Excitability and Neuropsychological Behavior Changes Following COVID-19 Infection in the Human Brain
1 other identifier
observational
48
0 countries
N/A
Brief Summary
The global COVID-19 pandemic has now led to millions of infections worldwide. It produces long-lasting changes in the general physiology of multiple organs, including the brain. Thus, this study aimed to comprehensively understand the cortical excitability and neuropsychological behavior changes in patients following SARS-CoV-2.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2023
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2023
CompletedFirst Submitted
Initial submission to the registry
July 24, 2023
CompletedFirst Posted
Study publicly available on registry
July 27, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2023
CompletedJuly 27, 2023
July 1, 2023
1 month
July 24, 2023
July 24, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The cortical excitability changes following COVID-19 infection.
This was assessed by single/paired pulse TMS procedures.
January 2023 to March 2023
Secondary Outcomes (1)
The neuropsychological behaviors following COVID-19 infection.
January 2023 to March 2023
Study Arms (2)
Uninfected
Subjects who had recovered from SARS-CoV-2 infection
Infected
Subjects who had not been infected with SARS-CoV-2.
Eligibility Criteria
The medical record of subjects who received cognitive function and TMS tests between January 2023 and March 2023 by our investigation group were retrospectively analyzed.
You may qualify if:
- \. Age between 18 and 60 years; 2. Completed the TMS and cognitive function tests; 3. Without physical discomfort or special physiological conditions (e.g., female subjects in their menstrual cycle or ovulation)
You may not qualify if:
- \. Had previous history of neurological or psychiatric disorders; 2. Had cognitive impairment or use of recreational or therapeutic psychoactive drugs within the past three months;3. Had severe hepatic or renal impairment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RenJi Hospitallead
Related Publications (1)
Wang Y, Yang H, Wang C, Yuan TF, Zhang S. Reduced risk tolerance and cortical excitability following COVID-19 infection. CNS Neurosci Ther. 2024 Aug;30(8):e14879. doi: 10.1111/cns.14879. No abstract available.
PMID: 39107954DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 24, 2023
First Posted
July 27, 2023
Study Start
July 1, 2023
Primary Completion
August 1, 2023
Study Completion
September 1, 2023
Last Updated
July 27, 2023
Record last verified: 2023-07